Endoscopic and surgical management of early esophageal cancer: Current evidence and evolving oncologic strategies

Abstract

Early esophageal cancer, defined as disease confined to the mucosa or superficial submucosa, represents a stage at which curative treatment can be achieved with minimally invasive approaches. Historically, esophagectomy was the standard treatment; however, it is associated with substantial morbidity and mortality. Advances in endoscopic techniques, particularly endoscopic mucosal resection and endoscopic submucosal dissection, have shifted management toward organ-preserving strategies in appropriately selected patients. This narrative review provides an updated overview of endoscopic and surgical treatment strategies for early esophageal cancer, with emphasis on risk stratification, clinical decision-making, and interpretation of current evidence. Endoscopic mucosal resection remains suitable for smaller, superficial lesions, whereas endoscopic submucosal dissection enables en bloc resection of larger or more complex lesions with higher rates of complete resection and lower recurrence. Surgical resection continues to play an essential role in patients with submucosal invasion or high-risk histologic features, including lymphovascular invasion and poor differentiation. While endoscopic therapy offers favorable outcomes with reduced morbidity and improved quality of life, these results are largely derived from retrospective studies and high-volume centers, and may not be fully generalizable. Careful patient selection and multidisciplinary evaluation remain critical to optimize treatment outcomes. Future directions include refinement of risk stratification models, integration of advanced imaging and artificial intelligence, and expansion of training programs to support broader adoption of advanced endoscopic techniques.

Key Words: Esophageal cancer; Esophageal squamous cell carcinoma; Esophageal adenocarcinoma; Endoscopic therapy; Endoscopic mucosal resection; Endoscopic submucosal dissection

Core Tip: Early esophageal cancer represents a stage at which curative treatment can be achieved with favorable long-term outcomes. While esophagectomy remains an established oncologic standard, it is associated with substantial morbidity. Growing evidence supports endoscopic resection, including endoscopic mucosal resection and endoscopic submucosal dissection, as effective organ preserving alternatives for carefully selected patients with low risk of lymph node metastasis. Accurate staging and multidisciplinary evaluation are essential to optimize treatment selection. This minireview highlights current evidence comparing endoscopic and surgical strategies and discusses evolving technologies that are reshaping the management paradigm for early esophageal cancer.

INTRODUCTION

Esophageal cancer is among the most aggressive malignancies of the gastrointestinal tract, characterized by a poor prognosis and high mortality. It is the eighth most common cancer and the sixth leading cause of cancer-related death globally[1-3]. The overall 5-year survival rate remains dismal, ranging from 15% to 25% worldwide, largely due to late-stage diagnosis and rapid disease progression[3]. The disease predominantly affects older adults, with a higher incidence in men.

The two main histological subtypes of esophageal cancer are esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC), each with distinct epidemiological and pathological features[4,5]. ESCC remains the predominant type in East Asia and parts of Africa, while EAC has become more prevalent in Western countries, often arising from Barrett’s esophagus.

For locally advanced disease, esophagectomy with or without neoadjuvant chemoradiotherapy remains the standard of care. However, esophagectomy is a highly invasive procedure associated with significant perioperative morbidity, long-term functional impairment, and considerable impact on quality of life[6-10]. Traditional open surgical approaches often involve large incisions through the neck, chest, or abdomen, leading to substantial physiological stress and prolonged recovery.

Recent advancements in endoscopic imaging, resection, and ablative technologies have transformed the management of early-stage esophageal cancer. Current international guidelines now recommend endoscopic resection as the first-line treatment for early esophageal cancers confined to the mucosa (T1a) without high-risk histologic features such as poor differentiation or lymphovascular invasion[11-13]. Emerging evidence suggests that endoscopic therapy offers comparable oncologic outcomes to surgery in carefully selected patients, while significantly reducing procedure-related morbidity and preserving esophageal function.

Accurate staging using endoscopic ultrasound, high-resolution imaging, and histopathological evaluation is essential for identifying appropriate candidates for endoscopic treatment. While accumulating evidence supports the safety and efficacy of endoscopic approaches, most available data are derived from retrospective studies and selected patient populations. As such, careful interpretation of outcomes and appropriate patient selection remain critical.

This minireview provides an updated overview of current endoscopic and surgical treatment strategies for early esophageal cancer, including indications, techniques, outcomes, and limitations. Particular emphasis is placed on risk stratification, clinical decision-making, and emerging challenges in the adoption of minimally invasive approaches across different practice settings.

METHODOLOGY

This narrative minireview was conducted to summarize current evidence on the endoscopic and surgical management of early esophageal cancer. A literature search was performed using PubMed, EMBASE, and Web of Science databases for studies published up to January 2026. Search terms included combinations of “early esophageal cancer”, “endoscopic mucosal resection”, “endoscopic submucosal dissection”, “esophagectomy”, “Barrett’s esophagus”, and “esophageal squamous cell carcinoma”. Relevant clinical studies, systematic reviews, meta-analyses, and international guidelines were prioritized. Particular emphasis was placed on studies evaluating treatment outcomes, risk stratification, and long-term oncologic results. As this is a narrative minireview, formal systematic inclusion and exclusion criteria were not applied. Instead, studies were selected based on clinical relevance, methodological quality, and contribution to current understanding of treatment strategies.

SURGICAL RESECTION OF EARLY ESOPHAGEAL CANCER (ESOPHAGECTOMY)

Esophagectomy has long been the definitive treatment for esophageal cancer and precancerous conditions such as Barrett’s esophagus with high grade dysplasia. While it offers complete resection of the primary tumor and regional lymph nodes, it is associated with significant postoperative morbidity, reported in 40%-50% of cases, and mortality rates ranging from 2%-9.5%. These risks are especially concerning for patients with multiple comorbidities or those who are not suitable surgical candidates[14]. The procedure involves removing the diseased portion of the esophagus along with the upper part of the stomach, including the gastroesophageal junction. The remaining esophagus is then connected to the stomach, which is reshaped into a conduit and pulled up into the chest or neck to restore gastrointestinal continuity. In some cases, a segment of the colon or small intestine is used as an alternative conduit when the stomach cannot be used[15,16].

Despite improvements in surgical techniques, esophagectomy remains a major operation with considerable impact on the body. Large incisions through the thoracic and abdominal cavities are often required, which contribute to the high risk of complications, including anastomotic leak, respiratory infections, and strictures[17]. The loss of the gastroesophageal junction, which acts as a natural barrier against reflux, frequently results in severe postoperative gastroesophageal reflux. Additionally, the reshaped stomach loses its normal reservoir function, leading to altered digestion and nutritional challenges[7,10,14,17]. In contrast, endoscopic resection techniques such as endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD) provide a less invasive alternative for early stage esophageal cancer[12,18-21]. These methods preserve the structure and function of the esophagus and stomach, avoid external incisions, and are associated with faster recovery and fewer complications[18-21].

ENDOSCOPIC RESECTION FOR EARLY ESOPHAGEAL CANCER

Endoscopic therapy provides a promising alternative to esophagectomy for carefully selected patients with early esophageal cancer. Its clinical application has expanded significantly over the past decade. Multiple studies have demonstrated that endoscopic treatment for dysplasia and early esophageal cancer offers survival outcomes comparable to surgery, but with reduced morbidity and preservation of esophageal anatomy and function[4,5,11].

A critical determinant in selecting candidates for endoscopic therapy is the risk of lymph node metastasis. Lesions confined to the mucosal layer (T1a) are associated with a very low risk of nodal involvement and are generally considered appropriate for endoscopic resection. In contrast, submucosal invasion (T1b), particularly beyond superficial layers, is associated with a significantly increased risk of lymph node metastasis. In addition to depth of invasion, histologic features such as lymphovascular invasion, poor tumor differentiation, and tumor size further influence metastatic risk. These factors must be carefully evaluated when determining whether endoscopic therapy alone is sufficient or whether additional surgical management is warranted.

However, endoscopic therapy is best suited for patients with low risk of regional lymph node metastasis. Careful staging and histological assessment are essential to identify appropriate candidates. A proportion of patients undergoing endoscopic treatment may experience local recurrence or persistent dysplasia. These individuals may require additional endoscopic intervention or, in some cases, conversion to surgical management.

Among the endoscopic techniques, the two most widely used approaches are EMR and ESD. EMR is typically used for smaller lesions confined to the mucosa, while ESD is preferred for larger or more complex lesions, including those involving the superficial submucosa. ESD allows for en bloc resection with clear margins, which is critical for accurate pathological evaluation and reducing recurrence[22-24].

In recent years, substantial evidence supporting ESD has emerged, particularly from East Asian countries, where the technique has become widely adopted[22-24]. With ongoing advances in technology, increasing availability of specialized training, and the establishment of quality assurance standards, ESD is poised to become a central component of the treatment algorithm for early stage esophageal malignancies. Representative ongoing and recent clinical trials evaluating endoscopic treatment strategies for early esophageal cancer are summarized in Table 1.

Table 1 Ongoing and recent clinical trials evaluating endoscopic treatment for early esophageal cancer.

Trial/registry	Study design	Population	Intervention	Primary outcome	Study status
JCOG0508	Prospective multicenter phase II	Superficial ESCC with minimal submucosal invasion	ESD followed by selective chemoradiotherapy	Overall survival, local control	Completed
JCOG1009/1010	Prospective multicenter	Superficial ESCC	ESD with adjuvant therapy	Disease-free survival	Completed
NCT02304181	Prospective cohort	Early esophageal neoplasia	ESD	En bloc and R0 resection rates	Completed
NCT03470246	Randomized controlled trial	Barrett’s-associated neoplasia	EMR + RFA vs EMR alone	Eradication of dysplasia	Completed
ChiCTR1800018892	Multicenter prospective	Early ESCC	ESD	Long-term survival and recurrence	Ongoing

ESCC: Esophageal squamous cell carcinoma; ESD: Endoscopic submucosal dissection; EMR: Endoscopic mucosal resection; RFA: Radiofrequency ablation.

EMR

EMR plays a central role in both the diagnosis and treatment of early esophageal cancers. It is particularly effective for superficial lesions confined to the mucosal layer. The two most commonly used techniques are ligation-assisted EMR and cap-assisted EMR. Both methods have demonstrated comparable efficacy and low complication rates[21,25,26].

Several studies have reported high success rates with EMR in early EAC, with complete remission rates reaching up to 98 percent and five-year survival rates of 98% in selected patients[27,28]. Manner and colleagues evaluated outcomes in patients with superficial submucosal invasion (T1bSM1) and observed a complete remission rate of 87% and a five-year survival rate of 84 percent. Notably, patients with lesions smaller than 2 centimeters achieved a remission rate of 97%, compared to 77% for those with lesions larger than 2 centimeters[29]. Complete resolution of dysplasia was reported in 87%-96% of patients. However, stricture formation occurred in up to 88% of cases, particularly among those who underwent large or circumferential resections.

EMR is also an effective treatment for ESCC limited to the mucosal layer. Tumors confined to the M1 or M2 layer are considered absolute indications for resection, while M3 or superficial submucosal tumors up to 200 micrometers in depth, with no clinical evidence of lymph node involvement, are relative indications. Studies on the use of EMR in ESCC have reported five-year disease specific survival rates of approximately 90%, with a low incidence of major complications[27-29]. However, recurrence rates are higher for lesions larger than 2 cm, likely due to incomplete resection at the tumor margins[30,31]. The most frequently reported complications of EMR include esophageal stricture formation in up to 38% of patients, bleeding in 5.8%-12%, and perforation in approximately 2%[30-32]. Strictures are more common following circumferential or near circumferential resections.

EMR is most effective for lesions smaller than 20 mm in diameter. Larger lesions often require piecemeal resection, which limits the ability to achieve complete (R0) resection and can compromise the pathological assessment of resection margins and depth of invasion[21-23,32]. To overcome these limitations, ESD is preferred for larger lesions, as it allows for en bloc resection. This enables more accurate histological evaluation and improves the likelihood of achieving curative resection.

ESD

ESD allows for en bloc resection and curative removal of esophageal lesions regardless of their size (Figure 1)[33,34]. It is particularly indicated for neoplastic lesions greater than 15 mm, non-lifting or fibrotic lesions, and those with a higher risk of submucosal invasion. ESD is technically more demanding than EMR and requires advanced endoscopic skills. It is not yet widely available in the United States, with only a limited number of centers offering this technique performed by trained endoscopists.

Figure 1 Endoscopic submucosal dissection for esophageal cancer resection. A: Iodophor staining of the lesion; B: Cauterization marking around the lesion and submucosal injection; C: Use duel knife to cut the mucosa around the lesion; D: Gradually separate the lesion from the muscularis propria by electric resection; E: Wound site after electrocoagulation hemostasis; F: Removed lesion specimen.

Most of the clinical experience and outcome data on ESD comes from Asia, particularly China and Japan, where the procedure has been extensively practiced. In these regions, it has demonstrated high efficacy and safety in managing superficial esophageal neoplasia involving the submucosal layer. A recent multicenter retrospective cohort study involving 368 patients who underwent ESD for superficial esophageal cancer reported a complete resection rate of 96.7%[34]. Complications such as perforation, bleeding, and strictures were reported but were generally managed with conservative treatment. More recent studies have confirmed that when performed by expert endoscopists at high volume centers, ESD achieves excellent long term outcomes. Reported five-year overall survival and disease specific survival rates range from 90 to 99 percent and up to 100%, respectively[35,36].

A recent meta-analysis comparing EMR and ESD in patients with superficial esophageal cancer showed that ESD resulted in a significantly higher complete resection rate (92.7% vs 52.7%) and a lower rate of local recurrence (0.3% vs 11.5%). However, patients undergoing ESD experienced a higher risk of perforation and longer procedure times[36].

Another meta-analysis that included 21 studies evaluating the use of ESD for esophageal cancer found a pooled en bloc resection rate of 99 percent. The pooled complete (R0) resection rate was 90 percent, with a slightly lower rate of 85 percent for tumors larger than 25 mm in diameter. The most common complications were esophageal stricture and perforation, with reported rates of 5% and 1%, respectively[36].

The advancement of endoscopic resection techniques, including the development and refinement of both EMR and ESD, has significantly expanded the role of endoscopy in the management of early esophageal cancer[4,26,30]. The choice of technique largely depends on lesion size, location, and histologic features. Overall, extensive evidence supports the effectiveness, safety, and long term success of these minimally invasive approaches. It is important to note that the majority of data supporting ESD originates from East Asia, where screening programs, case volume, and operator expertise are well established. In contrast, adoption in Western countries has been slower, partly due to differences in disease epidemiology and limited availability of specialized training. As a result, outcomes reported from high-volume centers in Asia may not be directly generalizable to lower-volume or less experienced settings. Careful patient selection, referral to experienced centers, and structured training programs are essential to ensure safe implementation in broader clinical practice.

Endoscopic resection vs surgical resection

Although direct comparative studies between esophagectomy and endoscopic therapies remain limited, available evidence suggests that endoscopic approaches are significantly safer for appropriately selected patients. Endoscopic therapy is associated with a very low procedure-related mortality rate, estimated at approximately 0.2%, though risks such as perforation and bleeding still exist[18-20]. Despite these favorable outcomes, comparisons between endoscopic and surgical approaches should be interpreted with caution. Much of the available evidence is derived from retrospective or observational studies, often involving highly selected patient populations. Variability in staging accuracy, definitions of curative resection, and follow-up duration further contributes to heterogeneity across studies.

As a result, conclusions regarding comparable oncologic outcomes are most applicable to carefully selected low-risk patients and may not be generalizable across all clinical settings. Minimally invasive endoscopic resection has gained widespread acceptance as a primary treatment strategy for early esophageal neoplasia. The main endoscopic techniques currently in use are EMR and ESD, particularly in patients with early tumors and low risk of lymph node metastasis. While EMR is effective for small and well-demarcated lesions, it is often inadequate for larger lesions due to the need for piecemeal resection, which may limit histological assessment and completeness of excision. In contrast, ESD allows for en bloc resection, providing more reliable margin control and precise pathological evaluation[30,35,36]. In addition to resection, several endoscopic ablative techniques are available. These include photodynamic therapy, radiofrequency ablation, cryotherapy, and argon plasma coagulation[18,20,35,36]. Such therapies can be used alone or in combination with resection to eradicate residual neoplastic tissue or treat metachronous lesions.

To avoid undertreatment of more advanced disease and to optimize outcomes, careful patient selection is critical. Accurate staging, multidisciplinary evaluation, and adherence to evidence-based criteria are essential to determine candidacy for endoscopic therapy. In this context, risk stratification based on tumor characteristics plays a central role in guiding treatment decisions. Patients can be broadly categorized into ultra-low, low, intermediate, and high-risk groups based on depth of invasion, tumor size, histologic differentiation, and presence of lymphovascular invasion.

In addition, validated prediction models, including criteria derived from Japanese studies such as the Japan Clinical Oncology Group framework, provide further support in estimating lymph node metastasis risk. These tools, when integrated with multidisciplinary evaluation, can help refine the selection of endoscopic therapy vs surgical resection in individual patients.

Compared to surgical resection, endoscopic therapy offers several advantages, including shorter procedure duration, preservation of esophageal anatomy and function, fewer complications, and faster recovery without the need for external incisions. In carefully selected patients, these approaches can achieve favorable long-term oncologic outcomes with improved quality of life. A comparative summary of key treatment characteristics and clinical outcomes is presented in Tables 2 and 3.

Table 2 Comparative outcomes of treatment modalities for early esophageal cancer.

Outcome	EMR	ESD	Esophagectomy
En bloc resection rate	Low–moderate (piecemeal common for larger lesions)	High (> 90%-95%)	Not applicable
R0 resection rate	Moderate (lower for large lesions)	High (approximately 85%-95%)	High
Local recurrence rate	Higher (up to 10%-20%)	Low (< 1%-5%)	Very low
5-year overall survival	Approximately 85%-98% (selected patients)	Approximately 90%-99% (selected patients)	Approximately 85%-95%
Procedure-related mortality	Very low (< 0.5%)	Very low (< 0.5%)	Higher (2%-9%)
Major adverse events	Bleeding, stricture	Perforation, stricture	Pulmonary complications, anastomotic leak

ESD: Endoscopic submucosal dissection; EMR: Endoscopic mucosal resection.

Table 3 Comparison of treatment strategies for early esophageal cancer.

Treatment strategy	Advantages	Limitations
Esophagectomy	Complete tumor and lymph node removal; established oncologic standard for invasive disease	Highly invasive; significant perioperative morbidity and mortality; long recovery; loss of gastroesophageal junction; impaired quality of life
Endoscopic mucosal resection	Minimally invasive; low procedure-related mortality; effective for small, superficial mucosal lesions; short recovery time	Limited to small lesions; often requires piecemeal resection; reduced accuracy of pathological margin assessment; higher local recurrence for large lesions
Endoscopic submucosal dissection	En bloc resection regardless of lesion size; precise pathological evaluation; lower recurrence rates; organ preservation	Technically demanding; longer procedure time; higher risk of perforation and stricture; limited availability in some regions

A simplified treatment algorithm for early esophageal cancer is illustrated in Figure 2. This algorithm outlines a stepwise approach to clinical decision-making, in which patients with mucosal disease and no high-risk features are directed toward endoscopic resection, whereas those with submucosal invasion or adverse histologic characteristics are considered for surgical or multimodal treatment. This framework emphasizes the central role of risk stratification and multidisciplinary evaluation in optimizing treatment selection. To further support clinical decision-making, a proposed risk stratification framework with corresponding treatment recommendations is summarized in Table 4. In addition, key clinicopathologic factors influencing treatment selection, including tumor size, depth of invasion, and histological subtype, are outlined in Table 5.

Figure 2 Treatment algorithm for early esophageal cancer. Patients with suspected early esophageal neoplasia undergo diagnostic endoscopy with biopsy and staging evaluation, including endoscopic ultrasound when appropriate. Low-risk mucosal lesions (T1a), without adverse histologic features, are treated with endoscopic resection using endoscopic mucosal resection or endoscopic submucosal dissection, followed by adjunctive ablative therapy and endoscopic surveillance as indicated. High-risk lesions or non-curative resections require multidisciplinary evaluation and consideration of esophagectomy, with or without chemoradiotherapy, or definitive oncologic therapy. APC: Argon plasma coagulation; EUS: Endoscopic ultrasound; LVI: Lymphovascular invasion; EMR: Endoscopic mucosal resection; ESD: Endoscopic submucosal dissection; RFA: Radiofrequency ablation.

Table 4 Risk stratification and treatment recommendations for early esophageal cancer.

Risk category	Tumor characteristics	Lymph node risk	Recommended treatment
Ultra-low risk	T1a (M1-M2), well differentiated, no LVI	Minimal (< 1%)	EMR or ESD
Low risk	T1a (M3), small lesions, no LVI	Low (approximately 1%-5%)	ESD preferred
Intermediate risk	T1b (SM1), no LVI, favorable histology	Moderate (approximately 5%-15%)	ESD ± additional therapy or surgery
High risk	T1b (deep SM), LVI+, poor differentiation	High (> 20%)	Surgical resection ± chemoradiotherapy

ESD: Endoscopic submucosal dissection; EMR: Endoscopic mucosal resection; LVI: Lymphovascular invasion.

Table 5 Stratified treatment considerations based on tumor characteristics.

Factor	Category	Clinical implication	Preferred approach
Tumor size	≤ 2 cm	Higher likelihood of en bloc resection	EMR or ESD
	> 2 cm	Increased risk of incomplete resection	ESD preferred
Depth of invasion	M1-M2	Minimal nodal risk	Endoscopic therapy
	M3-SM1	Intermediate nodal risk	ESD ± surgery
Histology	ESCC	Higher nodal risk with invasion	Careful selection
	EAC	Lower nodal risk in early stage	Endoscopic therapy favored

ESD: Endoscopic submucosal dissection; EMR: Endoscopic mucosal resection; ESCC: Esophageal squamous cell carcinoma; EAC: Esophageal adenocarcinoma.

Post-treatment surveillance and follow-up

Careful post-treatment surveillance is essential following both endoscopic and surgical management of early esophageal cancer. Patients treated with endoscopic resection remain at risk for local recurrence, metachronous neoplasia, and progression of underlying Barrett’s esophagus or squamous dysplasia. As a result, structured endoscopic follow-up is a critical component of long-term disease control[5,6,11,34,36].

After curative endoscopic resection, current guidelines recommend repeat endoscopy at short intervals during the first year, followed by periodic surveillance thereafter. Surveillance protocols typically include high-resolution white-light endoscopy, chromoendoscopy or virtual chromoendoscopy, and targeted biopsies of the resection site and surrounding mucosa. Adjunctive ablative therapies may be applied when residual dysplasia or Barrett’s epithelium is identified[21,24].

Patients who undergo esophagectomy also require long-term follow-up, focusing on detection of recurrence, management of postoperative complications, and nutritional monitoring. Follow-up strategies commonly involve clinical assessment, imaging studies when indicated, and endoscopic evaluation in selected cases. A multidisciplinary approach is essential in tailoring surveillance intensity based on tumor characteristics, resection margins, histologic risk factors, and patient comorbidities. Early detection of recurrence through structured follow-up allows timely intervention and contributes to favorable long-term outcomes.

Advances in endoscopic surveillance

Recent technological advancements have significantly expanded the role of endoscopy in the surveillance of patients treated for early esophageal cancer. High-resolution endoscopy combined with image-enhanced techniques, such as narrow-band imaging and virtual chromoendoscopy, has improved visualization of subtle mucosal and vascular abnormalities, enabling earlier detection of recurrent or metachronous neoplasia.

Artificial intelligence-assisted endoscopic systems represent a major emerging development in surveillance. Deep learning-based algorithms have demonstrated high sensitivity for detecting early esophageal neoplasia and dysplasia, even in lesions that are difficult to identify with conventional imaging. These tools may reduce interobserver variability and improve diagnostic accuracy, particularly in high-risk surveillance populations[4,6,11,36]. In addition, surveillance strategies are increasingly being tailored according to individual risk profiles, incorporating factors such as histologic features, depth of invasion, resection margins, and underlying Barrett’s esophagus or squamous dysplasia. Risk-adapted surveillance protocols allow more intensive monitoring of high-risk patients while minimizing unnecessary procedures in low-risk individuals[6,11]. Together, these advances support a more precise, efficient, and patient-centered approach to long-term surveillance after endoscopic treatment of early esophageal cancer.

Approach to suspected esophageal cancer when endoscopy is negative

Although endoscopy remains the cornerstone for the diagnosis of esophageal cancer, false-negative examinations can occur, particularly in cases of subtle, flat, subepithelial, or infiltrative lesions. When clinical suspicion persists despite an initial negative endoscopic evaluation, further diagnostic assessment is warranted. Repeat endoscopy performed by an experienced endoscopist, with careful inspection using high-resolution imaging and image-enhanced techniques, is often the first step. Targeted biopsies, random sampling of suspicious areas, and endoscopic ultrasound may help identify lesions not apparent on standard white-light endoscopy.

Cross-sectional imaging, including computed tomography or positron emission tomography, may be useful when symptoms, laboratory findings, or imaging suggest malignancy despite negative endoscopic findings. In selected cases, advanced techniques such as confocal laser endomicroscopy or endoscopic optical coherence tomography may provide additional diagnostic information.

Importantly, patients with persistent symptoms or high-risk features should be discussed in a multidisciplinary setting. Surgical exploration or empiric treatment should be considered only after comprehensive evaluation, balancing diagnostic yield against procedural risk. Recognizing the limitations of endoscopy and adopting a systematic diagnostic approach is essential for minimizing delayed or missed diagnoses of esophageal cancer.

CONCLUSION

The global burden of esophageal cancer continues to rise, with notably increasing incidence in countries such as China and Japan. Despite advances in diagnosis and treatment, the overall five-year survival rate remains low, especially for patients diagnosed at advanced stages. Esophagectomy has long been considered the gold standard for curative treatment of advanced esophageal lesions. However, the high rates of perioperative morbidity and mortality associated with surgical resection have prompted a paradigm shift toward less invasive alternatives.

Over the past decade, significant progress in endoscopic imaging and resection technologies has led to earlier detection and more effective management of superficial esophageal neoplasia. Endoscopic treatment modalities, including EMR, ESD, and various ablative therapies, have demonstrated excellent outcomes in appropriately selected patients. These approaches are particularly valuable for individuals with early stage tumors confined to the mucosal or superficial submucosal layers and without high risk features for lymph node metastasis. Endoscopic therapy is now well established as a first-line treatment for early esophageal cancer in many clinical guidelines. Surgery is increasingly reserved for patients with invasive disease or those who are not candidates for curative endoscopic resection. The goal is to provide the least invasive yet most effective treatment, tailored to the patient’s clinical condition, tumor characteristics, and risk profile.

Despite these advances, several important limitations remain. Much of the available evidence is derived from retrospective studies and high-volume centers, with limited representation from Western populations. Variability in expertise, staging accuracy, and patient selection continues to influence outcomes and limits generalizability. Future research should focus on prospective and randomized studies, development of standardized risk stratification models, and expansion of structured training programs to support safe implementation of advanced endoscopic techniques. Ultimately, the management of early esophageal cancer should be guided by a multidisciplinary approach that integrates accurate staging, individualized risk assessment, and careful selection of treatment modality to achieve the optimal balance between oncologic efficacy and quality of life.